Journal Article

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance

Choudhry, Priya, Nix, Matthew A., Nieves Vasquez, Wilson, Wiita, Arun P., Wells, James A., Wolf, Jeffrey L., Driessen, Christoph, Prakash, Sonam, Ramos, Emilio, Talbot, Alexis, Mullins, R. Dyche, Tuomivaara, Sami T., Lopez-Girona, Antonia, Naik, Akul, Posey, Avery D., Patiño-Escobar, Bonell, Leung, Kevin K., Vandenberg, Scott, Wong, Sandy W., Kasap, Corynn, Ferguson, Ian D., Hale, Martina, Shah, Nina, Kishishita, Audrey, Eyquem, Justin, Besse, Lenka, Lin, Yu-Hsiu T., Miao, Weili, Martin, Thomas G.

2022

Overview

The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma surfaceome at baseline, in drug resistance, and in response to acute drug treatment. We provide a scoring system for surface antigens and identify CCR10 as a promising target in this disease expressed widely on malignant plasma cells. We engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting CCR10 using its natural ligand CCL27. In myeloma models we identify proteins that could serve as markers of resistance to bortezomib and lenalidomide, including CD53, CD10, EVI2B, and CD33. We find that acute lenalidomide treatment increases activity of MUC1-targeting CAR-T cells through antigen upregulation. Finally, we develop a miniaturized surface proteomic protocol for profiling primary plasma cell samples with low inputs. These approaches and datasets may contribute to the biological, therapeutic, and diagnostic understanding of myeloma. The myeloma cell surface proteome regulates plasma cell biology and delineates therapy targets. Here, the authors profile the myeloma surfaceome at baseline and in drug resistance, finding the potential target CCR10, and include a streamlined approach to primary sample analysis.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 38 / 38/91 / 631/1647/296 / 631/45/475 / 631/45/612/1237 / 631/67/1990/804 / 82/58 / Antigens / Bortezomib / Cell surface / Chimeric antigen receptors / Drug Resistance / Glycoproteins / Humanities and Social Sciences / Humans / Immunotherapy / Immunotherapy - methods / Inhibitor drugs / Lenalidomide - therapeutic use / Lymphocytes / Lymphocytes T / Markers / Microenvironments / multidisciplinary / Multiple myeloma / Multiple Myeloma - drug therapy / Multiple Myeloma - pathology / Plasma cells / Proteins / Proteomes / Proteomics / Science / Science (multidisciplinary) / Surface antigens / Tumor Microenvironment / Tumors